3-nitropropionic acid has been researched along with Dyskinesia Syndromes in 12 studies
3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE
3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Reactive astrocytosis seems to be strongly implicated in the development and maintenance of inflammatory and neurodegenerative disorders." | 5.36 | Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats. ( Bianco, MR; Cirillo, G; Maggio, N; Papa, M; Sellitti, S; Vollono, C, 2010) |
| "The 3-nitropropionic acid animal model is a model where excitotoxicity, mitochondrial dysfunction and oxidative stress, mechanisms common to various neurodegenerative diseases, are involved." | 3.71 | Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation. ( Angevaren, M; Appels, M; de Bruijn, C; de Vente, J; Prickaerts, J; Steinbusch, HW; Teunissen, CE, 2001) |
| "Reactive astrocytosis seems to be strongly implicated in the development and maintenance of inflammatory and neurodegenerative disorders." | 1.36 | Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats. ( Bianco, MR; Cirillo, G; Maggio, N; Papa, M; Sellitti, S; Vollono, C, 2010) |
| "Animals with these Huntington's disease-like lesions showed spontaneous motor symptoms including mild dystonia, bradykinesia and gait abnormalities, which were barely detectable on visual inspection but could be readily identified and quantified by computerized video analysis." | 1.30 | Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. ( Brouillet, E; Dolan, R; Guyot, MC; Hantraye, P; Maziére, M; Palfi, S, 1997) |
| "Cotreatment with riluzole (4 mg/kg i." | 1.30 | Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. ( Brouillet, E; Guyot, MC; Hantraye, P; Mary, V; Palfi, S; Peschanski, M; Riche, D; Stutzmann, JM; Wahl, F, 1997) |
| " In addition, it was checked that this neuroprotective effect of riluzole against systemic 3-nitropropionic acid did not result from a decreased bioavailability of the neurotoxin or a direct action of riluzole on 3-nitropropionic acid-induced inhibition of succinate dehydrogenase." | 1.30 | Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. ( Brouillet, E; Guyot, MC; Hantraye, P; Mazière, M; Palfi, S; Stutzmann, JM, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Rahi, V | 3 |
| Ram, P | 3 |
| Kumar, P | 3 |
| Ranganayaki, S | 1 |
| Jamshidi, N | 1 |
| Aiyaz, M | 1 |
| Rashmi, SK | 1 |
| Gayathri, N | 1 |
| Harsha, PK | 1 |
| Padmanabhan, B | 1 |
| Srinivas Bharath, MM | 1 |
| Li, XM | 1 |
| Zhu, BG | 1 |
| Ni, JB | 1 |
| Cao, CY | 1 |
| Zhang, JP | 1 |
| Zhao, XD | 1 |
| Zhu, RS | 1 |
| Cirillo, G | 1 |
| Maggio, N | 1 |
| Bianco, MR | 1 |
| Vollono, C | 1 |
| Sellitti, S | 1 |
| Papa, M | 1 |
| Stefanova, N | 1 |
| Reindl, M | 1 |
| Neumann, M | 1 |
| Haass, C | 1 |
| Poewe, W | 1 |
| Kahle, PJ | 1 |
| Wenning, GK | 1 |
| de Lago, E | 1 |
| Fernández-Ruiz, J | 1 |
| Ortega-Gutiérrez, S | 1 |
| Cabranes, A | 1 |
| Pryce, G | 1 |
| Baker, D | 1 |
| López-Rodríguez, M | 1 |
| Ramos, JA | 1 |
| Silva-Adaya, D | 1 |
| Pérez-De La Cruz, V | 1 |
| Herrera-Mundo, MN | 1 |
| Mendoza-Macedo, K | 1 |
| Villeda-Hernández, J | 1 |
| Binienda, Z | 1 |
| Ali, SF | 1 |
| Santamaría, A | 1 |
| Guyot, MC | 3 |
| Hantraye, P | 3 |
| Dolan, R | 1 |
| Palfi, S | 3 |
| Maziére, M | 2 |
| Brouillet, E | 3 |
| Riche, D | 1 |
| Mary, V | 1 |
| Wahl, F | 1 |
| Peschanski, M | 1 |
| Stutzmann, JM | 2 |
| Shear, DA | 1 |
| Haik, KL | 1 |
| Dunbar, GL | 1 |
| Teunissen, CE | 1 |
| Steinbusch, HW | 1 |
| Angevaren, M | 1 |
| Appels, M | 1 |
| de Bruijn, C | 1 |
| Prickaerts, J | 1 |
| de Vente, J | 1 |
12 other studies available for 3-nitropropionic acid and Dyskinesia Syndromes
| Article | Year |
|---|---|
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Inhibition of mitochondrial complex II in neuronal cells triggers unique pathways culminating in autophagy with implications for neurodegeneration.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Autophagy; Cell Death; Cell Line; Cell Survival; Cells, Cultur | 2021 |
No spatial memory deficit exists in Kunming mice that recently recovered from motor defects following 3-nitropropionic acid intoxication.
Topics: Animals; Behavior, Animal; Convulsants; Male; Maze Learning; Memory Disorders; Mice; Mice, Inbred St | 2009 |
Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats.
Topics: Animals; Astrocytes; Basal Ganglia; Basal Ganglia Diseases; Behavior, Animal; Disability Evaluation; | 2010 |
Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Astrocytes; Disea | 2005 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of L-carnitine.
Topics: Animals; Antioxidants; Brain; Carnitine; Convulsants; Disease Models, Animal; Dose-Response Relation | 2008 |
Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid.
Topics: Analysis of Variance; Animals; Corpus Striatum; Dihydrolipoamide Dehydrogenase; Drug Administration | 1997 |
Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.
Topics: Acetylcholinesterase; Animals; Antiparkinson Agents; Apomorphine; Caudate Nucleus; Corpus Striatum; | 1997 |
Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats.
Topics: Animals; Antihypertensive Agents; Corpus Striatum; Injections, Intraperitoneal; Male; Malonates; Mic | 1997 |
Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats.
Topics: Animals; Behavior, Animal; Cerebral Ventricles; Cognition Disorders; Corpus Striatum; Creatine; Male | 2000 |
Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation.
Topics: Animals; Behavior, Animal; Discrimination Learning; Disease Models, Animal; Gait Disorders, Neurolog | 2001 |